APA

Barros P. O., Cassano T., Hygino J., Ferreira T. B., Centurião N., Kasahara T. M., Andrade R. M., Linhares U. C., Andrade A. F. B., Vasconcelos C. C. F., Alvarenga R., Marignier R. & Bento C. A. M. (20160623). Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. : Clinical and experimental immunology.

Chicago

Barros P O, Cassano T, Hygino J, Ferreira T B, Centurião N, Kasahara T M, Andrade R M, Linhares U C, Andrade A F B, Vasconcelos C C F, Alvarenga R, Marignier R and Bento C A M. 20160623. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. : Clinical and experimental immunology.

Harvard

Barros P. O., Cassano T., Hygino J., Ferreira T. B., Centurião N., Kasahara T. M., Andrade R. M., Linhares U. C., Andrade A. F. B., Vasconcelos C. C. F., Alvarenga R., Marignier R. and Bento C. A. M. (20160623). Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. : Clinical and experimental immunology.

MLA

Barros P O, Cassano T, Hygino J, Ferreira T B, Centurião N, Kasahara T M, Andrade R M, Linhares U C, Andrade A F B, Vasconcelos C C F, Alvarenga R, Marignier R and Bento C A M. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. : Clinical and experimental immunology. 20160623.